OBI Pharma Granted FDA Orphan Drug Designation for OBI-888 for the Treatment of Pancreatic Cancer
First Orphan Drug Designation for OBI-888, a novel first-in-class Monoclonal Antibody targeting Globo H, a glycolipid antigen found on multiple tumor types.
TAIPEI, Taiwan, Nov. 21, 2018 -- (Healthcare Sales & Marketing Network) -- OBI Pharma, Inc., a ... Biopharmaceuticals, Oncology, FDA OBI Pharma, Pancreatic Cancer, immunotherapy, Globo H
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Immunotherapy | Marketing | Pancreas | Pancreatic Cancer | Pharmaceuticals | Taiwan Health